Response rates, DOR, and survival outcomes for the entire cohort and by histology
| Outcome . | Entire cohort (N = 96) . | DLBCL (N = 51) . | HGBL (N = 9) . | PMBCL (N = 8) . | THRLBCL (N = 6) . | Transformed lymphomas (N = 20) . |
|---|---|---|---|---|---|---|
| ORR, % | 18.8 | 11.8 | 22.2 | 62.5 | 33.3 | 10 |
| CR, % | 10.4 | 7.8 | 11.1 | 25 | 16.7 | 5 |
| Median DOR, d (95% CI) | 221 (84, -) | 226 (56, -) | 569 (83, -) | 221 (221, -) | 176 (84, -) | 478 (88, -) |
| Median PFS, d (95% CI) | 54 (48-76) | 55 (48-78) | 42 (28, -) | 157 (149, -) | 38 (29, -) | 48 (34-98) |
| Median OS, d (95% CI) | 159 (123-265) | 142 (108-333) | 351 (159, -) | 244 (151, -) | 350 (42, -) | 92 (74-201) |
| Outcome . | Entire cohort (N = 96) . | DLBCL (N = 51) . | HGBL (N = 9) . | PMBCL (N = 8) . | THRLBCL (N = 6) . | Transformed lymphomas (N = 20) . |
|---|---|---|---|---|---|---|
| ORR, % | 18.8 | 11.8 | 22.2 | 62.5 | 33.3 | 10 |
| CR, % | 10.4 | 7.8 | 11.1 | 25 | 16.7 | 5 |
| Median DOR, d (95% CI) | 221 (84, -) | 226 (56, -) | 569 (83, -) | 221 (221, -) | 176 (84, -) | 478 (88, -) |
| Median PFS, d (95% CI) | 54 (48-76) | 55 (48-78) | 42 (28, -) | 157 (149, -) | 38 (29, -) | 48 (34-98) |
| Median OS, d (95% CI) | 159 (123-265) | 142 (108-333) | 351 (159, -) | 244 (151, -) | 350 (42, -) | 92 (74-201) |